EN | UA
EN | UA

Help Support

Back

Sublingual formulation of Cyclobenzaprine eases sleep-related symptoms in patients with PTSD

Posttraumatic stress disorder Posttraumatic stress disorder
Posttraumatic stress disorder Posttraumatic stress disorder

What's new?

TNX-102 SL (sublingual formulation of Cyclobenzaprine) is well-tolerated and can effectively promote recovery from military-linked posttraumatic stress disorder.

As per the findings of a phase 3 randomized, placebo-controlled trial, monotherapy with 5.6 mg TNX-102 SL taken daily at bedtime can remarkably improve sleep disturbances in people suffering from posttraumatic stress disorder (PTSD), particularly those dealing with military-related trauma. This is a crucial finding, as sleep disturbances are a common and debilitating symptom of PTSD.

Megan E. Parmenter and other researchers examined the safety and efficiency of bedtime sublingual formulation of Cyclobenzaprine (TNX-102 SL) in military-linked PTSD at 44 U.S. outpatient psychiatric research clinics. Participants (aged between 18 and 75 years old) were randomly allocated in a 1:1 ratio to receive either 5.6 mg of TNX-102 SL (2 x TNX-102 SL 2.8 mg tablets) or placebo (2 x placebo SL tablets) for a duration of twelve weeks. Study visits occurred at screening, baseline, and at 2 (telephonic), 4, 8, and 12 weeks, or at the time of discontinuance if prior to week 12. 

Follow-up visits were conducted one week after the completion of the study for those not entering the twelve-week open-label extension study. While the primary assessment investigating alteration from baseline in Clinician Administered PTSD Scale [CAPS-5] total severity between study groups at week 12 did not show profound differences, there were notable improvements observed as early as week 4, particularly in sleep-related symptoms, as shown in Figure 1:

Secondary assessments further supported the potential benefits of TNX-102 SL use, showing improvements in both clinician and patient-reported outcomes (i.e. Clinician Global Impression of Improvement [CGI-I] at the 4th week and the Patient Global Impression of Change [PGIC] at the 12th week). No severe adverse events were documented. Importantly, TNX-102 SL was well-tolerated among participants, suggesting it could be a viable option for addressing PTSD symptoms.

The period since the occurrence of trauma acted as a factor distinguishing the therapeutic response according to the CAPS-5 assessment in the subgroup of individuals with ≤ 9 years since the initial event. Hence, targeting sleep disturbances with pharmacotherapy like TNX-102 SL appears to be a promising avenue for promoting recovery and improving overall quality of life.

Source:

Psychiatry Research

Article:

A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder

Authors:

Megan E. Parmenter et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: